About Reece
Reece is a leading capital markets lawyer and has extensive transactional experience in public and private capital raisings, mergers and acquisitions, and restructures. Reece’s broad experience includes applying his knowledge of the Corporations Act and ASX Listing Rules, as well as advising on governance, stakeholder management, employee share and option plans, and general commercial issues.
Reece has been consistently rated as a leading ‘Capital Markets’ and ‘Corporate M&A’ lawyer by Asia Pacific Legal 500 , providing ‘high quality advice, and being committed to the client’s needs’. Since 2017, Reece has been ranked in the Corporate Law category of Best Lawyers Australia.
His work has covered the life sciences, technology, telecommunications, travel, food and agribusiness, engineering and resources sectors. His clients include multinational corporations, ASX listed companies and early-stage companies with high growth potential.
Specialisations
Experience
IPOs
Numerous including Wagners, Over the Wire, Other Levels, Anatara Lifesciences, Corporate Travel Management, Seymour Whyte, Ausenco, Genera Biosystems, Invion, Provet and GBST.
Secondary raisings
Numerous including Ausenco, Corporate Travel Management, Carbon Energy, Viralytics, Tissue Therapies, Invion, Imugene, Lindsay Australia and Prescient Therapeutics.
M&A deals
For a number of leading clients throughout Australia and cross-border, including expansion of Corporate Travel Management and Technology One.
ChemGenex Pharmaceuticals Limited
Advising on the $225 million takeover of Cephalon, Inc.
Provet Holdings Limited
Advising on the $93.2 million acquisition under scheme of arrangements by Fortune 500 company, Henry Schein, Inc.
Seed capital and venture capital deals
Advising a range of specialised funds and investee companies with a focus on technology and creative industries.
International
Australian due diligence for Archer Daniels Midland’s US $1.2 billion sale of its cocoa business and Ontario Teachers Pension Plan’s US $1billion acquisition of Constellation Brands’ Canadian wine business.
Viralytics Limited
Advising on the $502 million acquisition of Viralytics Limited by Merck by scheme of arrangement.
River City Labs
Advising on the sale of River City Labs Group to Australian Computer Society (ACS).